PPIG and prostate carcinoma: Besides the effects from the binding of abiraterone to CYP enzymes, it may have several other anticancer effects, involving binding to the androgen receptor, 3β‐hydroxysteroid dehydrogenase inhibition as well as decreasing the levels of heat shock protein 27, a cytoprotective agent involved in drug resistance issues, in androgen-insensitive prostate cancer cells31.